rucaparib (Rubraca)

following a full submission assessed under the end of life and orphan medicine process:

rucaparib (Rubraca®) is accepted for restricted use within NHSScotland.

Indication under review: As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

SMC restriction: to patients who do not have a BRCA mutation

Rucaparib significantly improved progression free survival compared with placebo in a phase III study in patients with platinum-sensitive serous or endometrioid ovarian, primary peritoneal or fallopian tube carcinoma who had received at least two previous platinum based chemotherapy regimens.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.